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Objectives. Our investigation aimed at evaluating if bilateral subthalamic deep brain stimulation (DBS) could preserve working
capability in Parkinson’s disease (PD). Materials. We reviewed the data of 40 young (<60 year-old) PD patients who underwent
DBS implantation and had at least 2 years of follow-up. Patients were categorized based on their working capability at time of
surgery: “active job” group (𝑛 = 20) and “no job” group (𝑛 = 20). Baseline characteristics were comparable. Quality of life (EQ-5D)
and presence of active job were evaluated preoperatively and 2 years postoperatively. Results. Although similar (approximately 50%)
improvement was achieved in the severity of motor and major nonmotor symptoms in both groups, the postoperative quality of
life was significantly better in the “active job” group (0.687 versus 0.587, medians, 𝑝 < 0.05). Majority (80%) of “active job” group
members were able to preserve their job 2 years after the operation. However, only a minimal portion (5%) of the “no job” group
members was able to return to the world of active employees (𝑝 < 0.01). Conclusions. Although our study has several limitations,
our results suggest that in patients with active job the appropriately “early” usage of DBS might help preserve working capability
and gain higher improvement in quality of life.
The present scientific contribution is also dedicated to the 650th anniversary of the foundation of the University of
Pe´cs, Hungary
1. Introduction
The 27-year-old deep brain stimulation (DBS) revolution-
ized the treatment of movement disorders including drug-
resistant tremor, advanced Parkinson’s disease (PD) [1, 2],
and dystonia [3]. Based on its high efficacy and relatively
small side effect profile, more than 100,000 patients have
undergone DBS implantation worldwide [4]. Approximately
80% of indications for DBS are the pharmacologically not
efficiently treatable PD and considerably less patients receive
DBS for othermovement disorders [3, 5].Themost frequently
applied surgical target for PD is the bilateral subthalamic
DBS (STNDBS) capable of improving all cardinal symptoms.
Besides the symptomatic improvement, STN DBS can also
dramatically and permanently extend the ON time [6, 7] and
the health-related quality of life (HRQoL) [8, 9].
According to the current guidelines, STN DBS is only
indicated in the cases of drug-resistant tremor or severe
motor fluctuations unmanageable by pharmacological treat-
ment. The average disease duration at the time of surgery
is around 15 years [5], by when the health-related quality
of life (HRQoL) and sociocultural functioning are usually
impaired [10]. In general, the longer disease duration is
associated with the more likely appearance of levodopa-
resistant symptoms and therefore DBS-resistant symptoms
and higher impact on the working capability. One of the
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most important parts of patient selection therefore is the
appropriate timing of surgery [1, 11]. If the DBS implantation
is preformed “too late,” the presence and severity of DBS-
resistant symptoms (e.g., postural instability, neurocognitive
impairment, or speech problems) might interfere with or
worsen the outcome. On the contrary, if the surgery is per-
formed “too early,” we might operate on those patients who
could have been otherwise well treated pharmacologically
and needlessly expose them to the potential surgical risks.
Moreover, with “too early” operations we might also include
some nonidiopathic cases because the atypical features might
be hidden in the early stages of the disease course.
Based on the hypothesis [12–14] that the STN DBS treat-
ment applied at earlier stages of the disease may be superior
to the best medication, a multicenter study, called EarlyStim,
was initiated [15]. In this prospective study, patients receiving
STN DBS had significantly larger improvement in HRQoL
(−7.8 improvement onPDQ-38) than patients on bestmedical
treatment (+0.2 points worsening, 𝑝 = 0.002) [15]. Although
the contributors of EarlyStim study state that, in well-selected
cases where the “early” fluctuations impair the sociocultural
functioning and HRQoL, STN DBS might be superior to
optimal pharmacological treatment [15–17], there are lots of
debates on this issue [18, 19].
Inspired by the results of EarlyStim study, our research
group tried to evaluate if STN DBS might have an impact on
theworking status of PDpatients. Our a priori hypothesis was
that STN DBS could preserve working capability of patients
having an active job at the time of DBS implantation.
2. Materials and Methods
2.1. Patients. Those patients whowere included in the present
study underwent bilateral STN DBS implantation at Univer-
sity of Pe´cs and participated in our prospective DBS registry.
All patients signed an informed consent formapproved by the
Regional Ethical Board of University of Pe´cs. Patients were
eligible for STN DBS surgery (and therefore for participating
in our DBS registry) if they had the clinical diagnosis of PD
in accordance with the UK Brain Bank criteria [20] and at
least 5 years of documented disease duration, were under
the age of 75 years, had Parkinsonian motor symptoms or
dyskinesia that limited their ability to perform the activities
of daily living despite optimal oral pharmacological treat-
ment, had no dementia or major psychiatric illness, and
had no contraindication to surgery. Presence of dementia
was evaluated by the Hungarian validated version of Mattis
Dementia Rating Scale (MDRS) [21]. The scores on MDRS
can range from 0 to 144 with lower values indicating more
severe dementia. Scores on MDRS ≤125 points [21] and/or
fulfillment of Diagnostic and Statistical Manual of Mental
Disorders 4th Edition Text Revision criteria for dementia
were the exclusion criteria for STN DBS surgery.
Out of the group of patients having at least 2 years of
postoperative follow-up, first we identified those patientswho
had an active job at the time of their STN DBS surgery
and whose age was comparable with the inclusion criteria
of EarlyStim study (18–60 years) [17]. Having an active job
was assessed by direct inquiry. Only regular (>1 day/week),
either part-time or full-time, work was defined as active job.
Working capabilitywas categorized into the following groups:
(i) Full-time work (regular work, 5 days/week and 8
hours/day).
(ii) Part-time work (regular work, 1–5 days/week, 4–8
hours/day).
(iii) Not working, retired due to the disease.
(iv) Not working, retired not due to the disease.
(v) Never worked.
However, we did not consider those who participated
only in housework or performed hobby activities or unpaid
and irregular tasks as active workers. Altogether 20 PD
patients were identifiedmeeting the abovementioned criteria
whom we classified into the group of “active job.”
To perform pairwise comparison, we chose another 20
patients out of our registry who did not have an active job
at the time of their surgery (“no job” group) by the utilization
of a custom-made program. The automatic selection process
was made in a way that for each participant in the “active
job” groupwe picked a “partner” who had similar age, disease
duration, and fluctuation duration (in the range of ±2 years)
and the same disease type (tremor-dominant versus rigid-
akinetic type). These matched patients were considered as
the “no job” group. We utilized this automatic pairwise
selection process to create a “no job” groupwith balanced and
comparable baseline characteristics to the “active job” group.
2.2. Applied Tests. Changes in the working capability and the
health-related quality of life were considered as coprimary
endpoints. Our primary aim was to identify what portion of
young patients having active job at the time of DBS surgery
maintained their active job 2 years postoperatively. On the
contrary, we also investigated how many young patients not
having an active job at DBS initiation returned to work.
For evaluating HRQoL, the EuroQol Instrument (EQ-
5D) was assessed. Because the usage of EQ-5D requires
only 2 minutes and it was available in validated Hungarian
version [22] at the start of our DBS registry project, we
chose this HRQoL scale (and not the PDQ-39). EQ-5D
had been previously validated [23–25] and utilized in the
evaluation of different therapeutic approaches in PD [26, 27].
Moreover, it can also be applied to health-related economical
calculations [28]. EQ-5D consists of two major parts: a
five-item questionnaire and a visual analogue scale (VAS).
The first part of EQ-5D maps five different domains of
HRQoL: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression [22]. Based on the responses for the
five domains questionnaire, an index value vas calculated
(coprimary endpoint). The EQ-5D index can be in the range
from −0.52 to +1, the former representing a state worse
than death and the latter representing the best health-related
status [22]. For the Hungarian population, a change larger
than 0.0705 denotes clinicallymeaningful difference [29].The
response on VAS can range from 0 to 100, the higher values
meaning better HRQoL [22].
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Changes in major motor and nonmotor symptoms were
considered as secondary endpoints of the study. Severity
of Parkinson’s disease was rated by both Hoehn-Yahr Scale
(HYS) and Unified Parkinson’s Disease Rating Scale [30].
In agreement with the recommendations of the Movement
Disorders Society Task Force [31], the original (and not the
modified) HYS was utilized.Therefore, in our study, the stage
of 2.5 according to the modified HYS was considered as stage
3 (original HYS). The most important secondary outcome
of our study was the UPDRS Part III (Motor Examination),
where the score can range between 0 and 108 with higher
scores indicating worse function [30]. The secondary out-
come measures also included changes in activities in daily
living measured by the UPDRS Part II and Schwab and
England Scale (SES) [32]. Scores for the UPDRS-II can range
from 0 to 52 points with higher scores indicating worse
function [30]. The scores for SES can be in the range of
0–100 with higher values indicating better function. For
neuropsychiatric outcomes, the MDRS and Montgomery-
Asberg Depression Rating Scale (MADRS) were assessed.
Scores forMADRS can range from 0 to 60, with higher values
indicating more severe depression.
Each scale was assessed by three times (baseline, 1
week preoperatively, and follow-ups, 12 and 24 months
postoperatively). All sessions were videotaped enabling us to
reevaluate the HYS and UPDRS Part III with the exception
of rigidity by a blinded rater. Amount of antiparkinson med-
ication was calculated in levodopa equivalent dosage (LED)
[33].
2.3. Statistics. All statistical measurements were performed
by the IBM SPSS software package (IBM Inc., USA, version
22.0.1). The level of statistical significance was set at 0.05.
Because most parameters did not follow the normal distri-
bution, nonparametric tests were utilized and median values
with interquartile range (IQR: 25th–75th percentile) were
calculated.
Changes within each group (baseline versus follow-ups)
were tested by Friedman test (baseline versus 1st year of
follow-up versus 2nd year of follow-up). For intergroup
analyses (e.g., “active job” group versus “no job” group)
Mann-Whitney tests were applied. To evaluate changes in
dichotomous variables (e.g., having or not having an active
job), McNemar test was used.
To overcome the limitations of multiple comparisons,
we also applied a mixed-model two-way ANOVA where the
first factor has 2 levels and is independent (2 groups: having
an active job and not having a job) and the second factor
has 3 levels and is repeated (baseline, 1 year, and 2 years).
Because ANOVA can provide the difference between the 2
groups at all endpoints, there is no need for further post
hoc analyses. Furthermore, using this design, we can also
assess the interactions. Because simulation studies using a
variety of nonnormal distributions have shown that the false
positive rate is not affected very much by this violation of
the normality assumption [34–36], the nonnormal distri-
bution of the data did not preclude using such a statistical
design.
3. Results
3.1. Study Population. For the final analyses, the data of
only 20 pairs were included. Due to the pairwise group
selection, the most important baseline PD characteristics
were comparable (e.g., age, sex, disease duration, disease
type, and HYS, Table 1). Although we could not identify any
significant differences, the HY staging favored the “no job”
group by having more Stage 2 patients than the “active job”
group did.
The dosage of antiparkinson medication, severity of
motor symptoms (UPDRS-III), major neuropsychiatric
symptoms (MADRS andMDRS), andHRQoL (EQ-5D index
and VAS) were also similar at baseline (Table 2).
3.2. Working Capability. At baseline, 18 patients had a full-
time job and two patients had a part-time job in the “active
group.” Two years postoperatively, 16 patients from the
“active job” group (80%) still had an active job (full-time
job: 8 patients; part-time job: 8 patients). The reasons for
work discontinuation included the reach of official age limit
for pension (𝑛 = 1) and PD-related problems interfering
with working capability (e.g., fatigue and some degree of
fluctuation, 𝑛 = 3).
Despite the comparable baseline characteristics and sim-
ilar improvements in the motor symptoms and activities of
daily living, only a single person (5%) from the “no job”
group returned to the world of active work (McNemar test;
𝑝 < 0.01).
3.3. HRQoL. Both groups had similar HRQoL at baseline
(EQ-5D index values: 0.477 and 0.429, median values).These
values were below the 25th percentile of Hungarian popu-
lation norms [22]. (The 25th percentile population norms
for the 45–54 and 55–64 years age groups are 0.69 and
0.62, resp.) After bilateral STN DBS implantation, the EQ-
5D index significantly improved in both groups (Table 2,
Friedman tests), which clearly exceeded the threshold of
minimal clinically important difference (0.0705) [29]. How-
ever, 2 years after the operation, the “active job” group
members had significantly better HRQoL than the “no job”
patients did (Mann-Whitney test, 𝑝 < 0.001, Table 2) and
this difference was also clinically meaningful. Therefore, the
between-groups comparisons revealed better improvement
in the primary outcome (HRQoL) in the “active job” group.
The application of mixed-model two-way ANOVA with
Bonferroni correction further supported that HRQoL 2 years
postoperatively was better in the “active job” group than in
the “no job” group.
3.4. SecondaryOutcomes. As far as themotor symptomswere
concerned (UPDRS-III), both groups had similar baseline
characteristics and experienced similar improvement after
DBS implantation. Two years after the surgery, the motor
severity was still comparable in both groups. Moreover, the
changes in activities of daily living (SES and UPDRS-II)
and antiparkinson medication were also similar in both
groups. The only difference in the secondary outcomes was
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the significant improvement in MADRS score revealed by
Friedman test, whichwas present in the “active job” group but
was missing in the “no job” group.The application of mixed-
model two-way ANOVA with Bonferroni correction did not
identify any differences in the secondary outcomes.
4. Discussion
Our primary aim was to evaluate the hypothesized effect
of STN DBS on preserving the working capability of PD
patients. In our study, only those patients who were young
(<60 years) and had at least 2-year follow-up were included.
In the “active job” group, the participants had an active
job at the time of surgery but their working capability
was impaired by the motor symptoms (both tremor and
fluctuations) to some extent. For the “no job” group, we
selected patients having similar demographic and PD-related
baseline characteristics to perform reliable between-group
comparisons.
Our aim was to compare the efficacy of STN DBS on
patients having an active job (“active job” group) at the
time of surgery to the efficacy of STN DBS on patients
without an active job (“no job” group). In case of tremor-
dominant patients, the presence of drug-resistant tremor was
the indication for surgery, whereas, in rigid-akinetic patients,
the presence of severe fluctuations was the indication for
surgery. Because in both groups the number of tremor-
dominant and rigid-akinetic patients was identical due to the
pairwise selection, we believe our study design was suitable
to draw conclusions.
In the present study, themain focuswas to reveal if having
an active work at the time of DBS implantation could be a
prognostic factor for outcome and this working capability
could be preserved by STN DBS. One of the most important
findings of our study was that 80% of patients having an
active job at the time of surgery still had an active job 2 years
after theDBS implantation.Nevertheless, only a single patient
returned to the world of work in the “no job” group after
the successful STN DBS therapy. Therefore, we can conclude
that DBS might help preserve the working capability if it is
performed in patients with active job. On the contrary, if DBS
implantation is scheduled after losing the working capability,
it might be insufficient to help patients return to work.
The coprimary outcome variable was the change in
HRQoL. Patients in the “active job” group experienced higher
improvement in HRQoL than patients in the “no job” group
did despite the similar changes inmotor andmajor nonmotor
symptoms. This finding might suggest that having an active
job at the time of DBS surgery might have a beneficial effect
on the long-term outcome by being a positive predictive
factor.
The only difference in the secondary outcomes was the
significant improvement in MADRS score revealed by Fried-
man test. Because it was not confirmed by the multivariate
ANOVA, we considered this difference both clinically and
statistically irrelevant.
The authors are aware of the major limitations of their
study: not being randomized, placebo-controlled, double-
blind, multicenter, and prospective and having a relatively
small sample size. However, our results nicely fit to the con-
cept of EarlyStim because in some individuals the application
of “early” DBS might have a beneficial role in the socio-
cultural functioning. According to our results, in patients
with active job, the appropriately “early” usage of STN
DBS might help preserve sociocultural functioning and the
working capability in a two-year time frame and gain higher
improvement in HRQoL. Despite similar symptomatic con-
trol, patients receiving STN DBS after losing their working
capability seldom return to work again. In the opinion of
the authors, having an active job at the time of surgery
might be a positive predicting factor for a good outcome.
Because the maintenance of working capability is beneficial
not only for the patients but also for the healthcare providers,
further, larger, controlled trials are warranted to confirm this
hypothesis.
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